Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $219000.0.

  • Lineage Cell Therapeutics' Other Non Operating Income fell 5111.61% to $219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 3223.14%. This contributed to the annual value of -$670000.0 for FY2024, which is 2316.18% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Other Non Operating Income stood at $219000.0 for Q3 2025, which was down 5111.61% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Other Non Operating Income registered a high of $1.7 million during Q2 2025, and its lowest value of -$2.4 million during Q3 2021.
  • In the last 5 years, Lineage Cell Therapeutics' Other Non Operating Income had a median value of -$386000.0 in 2024 and averaged -$373210.5.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Non Operating Income tumbled by 29505.15% in 2022 and then soared by 54391.53% in 2025.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Other Non Operating Income stood at -$1.7 million in 2021, then surged by 123.72% to $398000.0 in 2022, then surged by 214.57% to $1.3 million in 2023, then tumbled by 130.83% to -$386000.0 in 2024, then soared by 156.74% to $219000.0 in 2025.
  • Its last three reported values are $219000.0 in Q3 2025, $1.7 million for Q2 2025, and -$231000.0 during Q1 2025.